

SDC 1: Factors associated with time to first viral load<1000 copies confirmed within 6 months (confirmed virological success=CVS) in the first two years of cART initiated before 12 months of age (ANRS-PEDIACAM Study, 2008-2013, Cameroon)

	Competing-risks regression in the presence of competing death						
	Estimated probability of CVS			Univariate analysis N=190		Multivariate analysis N=167	
	N	n	%	Crude sHR (95% CI)	p	Adjusted sHR (95% CI)	p
Baseline characteristics							
Sex							
Male	83	49	62.0	1	0.32		
Female	107	71	68.0	1.2 (0.8-1.7)			
Recruitment site							
HLD	40	27	70.0	1	0.24	1	0.64
CME/FCB	94	53	65.0	0.8 (0.5-1.3)		1.1 (0.7-1.8)	
CHE	56	40	77.0	1.2 (0.7-1.9)		1.3 (0.8-2.1)	
Age at cART initiation							
3-12 months	153	94	70.0	1	0.54	1	0.62
< 3 months	37	26	65.0	0.9 (0.6-1.3)		0.9 (0.5-1.4)	
Calendar year at cART initiation							
2010-2011	71	41	62.0	1	0.03	1	0.13
2008-2009	119	79	72.0	1.6 (1.1-2.2)		1.4 (0.9-2.0)	
Mode of inclusion							
At birth	60	39	70.0	1.0	0.37	1	0.43
After birth but before 7 months of age	130	81	64.0	0.8 (0.6-1.2)		1.2 (0.7-1.9)	
Time from HIV diagnosis to cART initiation							
≤2 weeks	132	82	67.0	1	0.94		
2-6 weeks	51	31	67.0	1.0 (0.6-1.5)			
6-12 weeks **	7						
Father's HIV status							
HIV-positive	45	31	70.0	1	0.81		
HIV-negative	43	28	68.0	1.0 (0.6-1.6)			
Unknown	102	61	64.0	0.9 (0.6-1.3)			
Mother receiving cART							
No	151	96	68.0	1	0.67		
Yes	39	24	64.0	0.9 (0.6-1.4)			
Father receiving cART							
No	154	96	64.0	1	0.39		
Yes	36	24	71.0	1.2 (0.8-1.8)			
Parents living with the infant							
Other relatives	24	13	57.0	1	0.29	1	0.86
Mother only	67	44	72.0	1.6 (0.9-3.0)		1.1 (0.6-2.1)	
Both parents	99	63	66.0	1.4 (0.8-2.4)		1.0 (0.5-1.9)	
Household size							
<5 people	90	57	66.0	1	0.99		
5 to 8 people	65	41	66.0	1.0 (0.7-1.5)			
≥9 people	35	22	66.0	1.0 (0.6-1.6)			
Running water at home							
No	86	64	62.0	1	0.36		
Yes	104	48	69.0	1.2 (0.8-1.7)			
Electricity at home							
No	21	11	58.0	1	0.42		
Yes	169	109	68.0	1.3 (0.7-2.5)			
Functional refrigerator at home							
No	97	56	61.0	1	0.17	1	0.37
Yes	93	64	70.0	1.2 (0.9-1.8)		1.2 (0.8-1.7)	

History of convulsions, diarrhea, hospitalization or infectious disease							
No	48	33	77.0	1	0.33		
Yes	132	87	64.0	0.8 (0.6-1.2)			
CD4 cell percentage							
<25.0 %	113	74	68.0	1	0.41		
≥25.0 %	77	46	63.0	0.9 (0.6-1.2)			
Viral load in log₁₀ copies/mL							
≥7.0	44	22	57.0	1	0.01	1	0.03
<7.0	146	98	74.0	1.7 (1.1-2.5)		1.7 (1.1-2.5)	
First cART regimen							
Lopinavir-based	123	83	71.0	1	0.10	1.0	0.90
Nevirapine-based	65	36	59.0	0.7 (0.5-1.1)		1.1 (0.6-1.7)	
3 nucleoside inhibitors*	2						
Prior exposure to nevirapine for prophylaxis							
Yes	90	52	70.0	1	0.16		
No	100	68	60.0	1.3 (0.9-1.9)			
Time-dependent characteristics							
Doses missed in the last 3 days, as reported by the carer							
≥1 missed dose				1	<0.01	1	0.01
No missed dose				1.4 (1.1-1.8)		1.4 (1.1-1.8)	

cART: combined antiretroviral therapy; **CVS:** virological success confirmed in the following 6 months; **N:** number of subjects; **n:** number of virological successes in the variable category from cART initiation to month 24; **%:** estimated probability of virological success; **95% CI:** 95% confidence interval; **sHR:** subhazard ratio; **p:** Wald test; **CME/FCB:** Centre Mère et Enfant de la Fondation Chantal Biya; **HLD:** Hôpital Laquintinie de Douala; **CHE:** Centre Hospitalier d'Essos; *convulsions, diarrhea or infectious disease; **: not included in the analysis.